ReviewInternational journal of nanomedicine2026
Recent Advances and Future Perspectives on Chitosan-Sago-Derived Sodium Starch Glycolate as a Biopolymeric Carrier for Alpha-Mangostin Nanoparticles in Wound Healing.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic wounds remain a major global health challenge, characterized by persistent inflammation, biofilm formation, oxidative stress, and impaired angiogenesis. Despite extensive research on biopolymers and phytochemicals for wound management, an integrated framework that combines agro-derived excipients with nanomedicine-based delivery systems is still limited. Objective: This review introduces a hybrid carrier strategy combining chitosan and sago-derived sodium starch glycolate (SSG) for the nanoformulation of α-mangostin (α-MG) in chronic wound therapy. The concept integrates biomaterials science and phytopharmaceutical delivery to address both biological and formulation-related challenges. Methods: A structured literature search was conducted using Scopus, PubMed, and Google Scholar to identify peer-reviewed studies on chitosan-based dressings, SSG functional properties, and α-MG nanoformulations. The findings were critically synthesized to evaluate physicochemical characteristics, biological activities, and translational considerations. Results: Chitosan provides hemostatic, antibiofilm, and immunomodulatory properties due to its cationic nature, while sago-derived SSG functions as a swelling matrix that regulates hydration and maintains moisture balance. Incorporation of α-MG, known for its antibacterial and antioxidant activity but limited by poor solubility, enables a biphasic delivery profile with an initial antimicrobial effect followed by sustained anti-inflammatory activity. Preclinical evidence indicates improved wound closure, reduced infection risk, and enhanced tissue regeneration. Conclusion: Chitosan-SSG hybrid systems represent a promising and sustainable platform for α-MG delivery in wound care. This review highlights their synergistic potential and outlines future directions for translational development in chronic wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.